{
    "nctId": "NCT00089973",
    "briefTitle": "Study Of Ispinesib In Subjects With Breast Cancer",
    "officialTitle": "Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Neoplasms, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage IIIB or Stage IV breast cancer\n* Previously received anthracycline and taxane therapy\n\nExclusion criteria:\n\n* Actively receiving anti-cancer therapy agent(s).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}